- Home
- CERS
CERS
Cerus Corporation
as 12-20-2024 4:00pm EST
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | CONCORD |
| Market Cap: | 324.3M | IPO Year: | 1997 |
| Target Price: | $3.17 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $2.59 | Next Earning Date: | 10-30-2024 |
| Revenue: | $176,229,000 | Revenue Growth: | 14.71% |
| Revenue Growth (this year): | 26.47% | Revenue Growth (next year): | 11.48% |
Stock Insider Trading Activity of Cerus Corporation (CERS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jensen Chrystal | CERS | Chief Legal Officer | Dec 16 '24 | Sell | $1.71 | 16,667 | $28,500.57 | 457,578 | |
| BJERKHOLT ERIC | CERS | Director | Dec 12 '24 | Sell | $1.79 | 20,000 | $35,700.00 | 162,133 |
Latest Cerus Corporation News
CERS Breaking Stock News: Dive into CERS Ticker-Specific Updates for Smart Investing
Simply Wall St.
24 days ago
Cerus And 2 Other US Penny Stocks To Watch
Business Wire
a month ago
Cerus Corporation to Participate in Upcoming Investor Conferences
Simply Wall St.
2 months ago
Cerus Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Thomson Reuters StreetEvents
2 months ago
Q3 2024 Cerus Corp Earnings Call
GuruFocus.com
2 months ago
Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Zacks
2 months ago
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Simply Wall St.
2 months ago
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
Associated Press Finance
2 months ago
Cerus: Q3 Earnings Snapshot
Compare CERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERS Cerus Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.